Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Liguria – page 3

810 clinical trials in Liguria, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Liguria at a glance
810
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

810 trials in Liguria

Open in trial search

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Greenwich LifeSciences Inc.

Migraine

Recruiting

Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Use of SYN2, Adenosine, and Regadenoson for Diagnosing Coronary Artery Disease in Patients with Suspected Heart Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Syn2bio S.A.

A study to assess the safety of anumigilimab in adults with sickle cell disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anumigilimab
  • Sponsor:CSL Behring LLC

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of ELA026 for Treatment of Secondary Hemophagocytic Lymphohistiocytosis in Patients with Lymphoma Who Have Not Received Previous Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:ELA026
  • Sponsor:Electra Therapeutics Inc.

Study on Eltrombopag for Treating Low and Intermediate Risk Myelodysplastic Syndromes in Patients with Thrombocytopenia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Associazione Qol-One

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study Comparing FOLFIRI with Cetuximab or Bevacizumab for First-Line Treatment in Patients with Metastatic Colorectal Cancer and Specific Genetic Profiles

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Azienda USL IRCCS Di Reggio Emilia

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Liguria

What the registry says about research in the country

01 HIV Treatment Research

Clinical research focusing on early treatment switching strategies for HIV-1 infected individuals who have achieved viral suppression. The trials examine the effectiveness of transitioning from three-drug to two-drug antiretroviral therapy.

  • Viral Suppression Maintenance
  • Treatment Simplification
  • Long-term Safety Assessment

The study aims to evaluate a novel approach using dolutegravir/lamivudine combination therapy, potentially offering patients a more streamlined treatment regimen while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.